Xavier Kurz

Xavier Kurz

Auto-generated profile, based on publicly available information

Xavier Kurz

European Medicines Agency Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2022 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
SWShirley V. Wang
Shirley V. Wang
APAnton Pottegård
Anton Pottegård
WCWilliam Crown
William Crown
PAPeter Arlett
Peter Arlett
DADarren M. Ashcroft
Darren M. Ashcroft
RWRebecca J. Williams
Rebecca J. Williams
Problem: Ambiguity in communication of key study parameters limits the utility of real‐world evidence (RWE) studies in healthcare decision‐making. Clear communication about data provenance, design, analysis, and implementation is needed. This would facilitate reproducibility, replication in independent data, and assessment of potential sources of bias.What We Did: The International Society for Pharmacoepidemiology (ISPE) and ISPOR–The Professional Society for Health Economics and Outcomes Research (ISPOR) convened a joint task force, including representation from key international stakeholders, to create a harmonized protocol template for RWE studies that evaluate a treatment effect and are intended to inform decision‐making. The template builds on existing efforts to improve transparency and incorporates recent insights regarding the level of detail needed to enable RWE study reproducibility. The overarching principle was to reach for sufficient clarity regarding data, design, analysis, and implementation to achieve 3 main goals. One, to help investigators thoroughly consider, then document their choices and rationale for key study parameters that define the causal question (e.g., target estimand), two, to facilitate decision‐making by enabling reviewers to readily assess potential for biases related to these choices, and three, to facilitate reproducibility.Strategies to Disseminate and Facilitate Use: Recognizing that the impact of this harmonized template relies on uptake, we have outlined a plan to introduce and pilot the template with key international stakeholders over the next 2 years.Conclusion: The HARmonized Protocol Template to Enhance Reproducibility (HARPER) helps to create a shared understanding of intended scientific decisions through a common text, tabular and visual structure. The template provides a set of core recommendations for clear and reproducible RWE study protocols and is intended to be used as a backbone throughout the research process from developing a valid study protocol, to registration, through implementation and reporting on those implementation decisions.

4 November 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
EBElisabeth Bakker
Elisabeth Bakker
KPKelly Plueschke
Kelly Plueschke
CJCarla J. Jonker
Carla J. Jonker
XKXavier Kurz
Xavier Kurz
VSViktoriia Starokozhko
Viktoriia Starokozhko
PMPeter G. M. Mol
Peter G. M. Mol
Real‐world data/evidence (RWD/RWE) may provide insightful information on medicines' clinical effects to guide regulatory decisions. While its contribution has been recognized for safety monitoring and disease epidemiology across medicines' life cycles, using RWD/RWE to demonstrate efficacy requires further evaluation. This study aimed to (i) characterize RWD/RWE presented by applicants to support claims on medicines' efficacy within initial marketing authorization applications (MAAs) and extension of indication applications (EoIs), and (ii) analyze the contribution of RWD/RWE to regulatory decisions on medicines' benefit–risk profile. RWD/RWE was included to support efficacy in 32 MAAs and 14 EoIs submitted 2018–2019. Of these, RWD/RWE was part of the preauthorization package of 16 MAAs and 10 EoIs, and was (i) considered supporting the regulatory decision in 10 applications (five MAAs, five EoIs), (ii) considered not supporting the regulatory decision in 11 (seven MAAs, four EoIs), and (iii) not addressed at all in the evaluation of 5 applications (four MAAs, one EoI). Common limitations of submitted RWD/RWE included missing data, lack of representativeness of populations, small sample size, absence of an adequate or prespecified analysis plan, and risk of several types of bias. The suitability of RWD/RWE in a given application still requires a case‐by‐case analysis considering its purpose of use, implying reflection on the data source, together with its assets and limitations, study objectives and designs, and the overall data package issued. Early interactions and continuous dialogues with regulators and relevant stakeholders is key to optimize fit‐for‐purpose RWE generation, enabling its broader use in medicines development.

11 January 2018 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
XKXavier Kurz
Xavier Kurz
SPSusana Perez‐Gutthann
Susana Perez‐Gutthann
TGthe ENCePP Steering Group
the ENCePP Steering Group

5 May 2020 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
APAnton Pottegård
Anton Pottegård
XKXavier Kurz
Xavier Kurz
NMNicholas Moore
Nicholas Moore
CCChristian F. Christiansen
Christian F. Christiansen
OKOlaf Klungel
Olaf Klungel

26 March 2017 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
JBJacoline Bouvy
Jacoline Bouvy
KBKevin Blake
Kevin Blake
JSJim Slattery
Jim Slattery
MBMarie L De Bruin
Marie L De Bruin
PAPeter Arlett
Peter Arlett
XKXavier Kurz
Xavier Kurz

1 December 2020 in Vaccine
Verified
Journal Article
Open access
MSMiriam Sturkenboom
Miriam Sturkenboom
PBPriya Bahri
Priya Bahri
ACAntonella Chiucchiuini
Antonella Chiucchiuini
TKTyra Grove Krause
Tyra Grove Krause
SHSusan Hahné
Susan Hahné
VBVincent Bauchau
Vincent Bauchau
The influenza A/H1N1 pandemic in 2009 taught us that the monitoring of vaccine benefits and risks in Europe had potential for improvement if different public and private stakeholders would collaborate better (public health institutes (PHIs), regulatory authorities, research institutes, vaccine manufacturers). The Innovative Medicines Initiative (IMI) subsequently issued a competitive call to establish a public-private partnership to build and test a novel system for monitoring vaccine benefits and risks in Europe. The ADVANCE project (Accelerated Development of Vaccine benefit-risk Collaboration in Europe) was created as a result. The objective of this paper is to describe the perspectives of key stakeholder groups of the ADVANCE consortium for vaccine benefit-risk monitoring and their views on how to build a European system addressing the needs and challenges of such monitoring. These perspectives and needs were assessed at the start of the ADVANCE project by the European Medicines Agency together with representatives of the main stakeholders in the field of vaccines within and outside the ADVANCE consortium (i.e. research institutes, public health institutes, medicines regulatory authorities, vaccine manufacturers, patient associations). Although all stakeholder representatives stated they conduct vaccine benefit-risk monitoring according to their own remit, needs and obligations, they are faced with similar challenges and needs for improved collaboration. A robust, rapid system yielding high-quality information on the benefits and risks of vaccines would therefore support their decision making. ADVANCE has developed such a system and has tested its performance in a series of proof of concept (POC) studies. The system, how it was used and the results from the POC studies are described in the papers in this supplementary issue.